On the 17th, Prime Minister Kim Bu-gyeom, through MBC, recommended the use of Celltrion's lekkrona, the US University of Washington said earlier that it was "not effective against Omicron."
The results of an important antibody treatment test conducted by a research team at the University of Washington Medical School were reported in the Washington Post on the 17th, and as a result of the study, "Regdanvimab (regdanvimab, product name: Rekkona) from Celltrion of Korea showed complete loss of inhibitory ability against omicron mutation." said.
The WP continued, “It has been confirmed that sotrovirab, jointly developed by Vir Biotechnology and GlaxoSmithKline (GSK, USA), has the ability to inhibit omicron mutation. The state has announced plans to distribute sotrovirab based on the number of infections, hospitalizations and omicron prevalence.
Prime Minister Kim said in MBC's 'Kim Jong-bae' on the 17th, "The EU has recognized that the lekkronage developed by Celltrion (omitted) is very effective in lowering the severity of aggravation. Doctors can use it with confidence (omitted),” he publicly announced the recommendation for use to medical staff.
Regarding the double test, which is a separate test for omicron in Korean diagnostic tests, “Even if our PCR test is positive, we can’t tell what kind of mutation it is at first. The PCR test kit itself is different from the UK and the like. For this reason, additional tests are required to determine whether it is a mutated virus," Chosun Ilbo reported on the 18th.
The Asian economy said, “If medical staff have a test tool that can discriminate between delta and omicron mutations, they can select an appropriate treatment, but otherwise, the treatment will be delayed and the fatality rate will increase, and only the degree of regional spread can determine whether or not omicron mutation is present. There is only one situation,” reported the 22nd of 'Nature'.
Health Minister Kwon Deok-cheol said, "Vaccination, especially the third vaccination, is the most effective safety device in the fight against Corona."
Celltrion Chairman Seo Jeong-jin in an exclusive interview with Hankyoreh Kwak Jeong-soo, editorial board member, in October last year, revealed that he would make a coronavirus-free country in the spring of next year (this year) with early diagnostic testing and treatment for the whole nation, and said about vaccines, “If you pay money, you can buy it.”
On the 7th, Prime Minister Kim met with Kim Jin-seok, deputy minister of the Ministry of Food and Drug Safety, representatives of four diagnostic kit development companies at the 'Omicron mutation response field meeting' at the Korea Centers for Disease Control and Prevention, and the government 'provided sufficient clinical samples in cooperation with foreign organizations to develop Omicron mutations'. , the 'rise of corporate stock prices' reacted first to 'the quarantine site'.